Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment Vafseo, prescribed by over 640 physicians in Q1.

A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections.

With initial pricing at $15,500 annually and post-TDAPA rates expected near $2,500, Akebia targets a $4–5 billion opportunity by expanding to non-dialysis CKD patients. A pilot launch with a major dialysis provider is set for Q3, covering 75–200 clinics, with broader availability expected in Q4 and a Phase 3 trial planned for later this year.

Akebia also reaffirmed strong sales momentum for Auryxia, its existing kidney treatment, despite generic competition. The company’s R&D pipeline includes AKB-909O for acute kidney injury and AKB-10108 for retinopathy of prematurity. Akebia aims to position Vafseo as the standard of care across CKD stages, supported by its ongoing VOICE trial targeting reduced hospitalizations. This strategic push underscores Akebia’s focus on delivering innovative solutions for chronic kidney care and expanding market reach amid competitive challenges.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. It has two FDA-approved products, Auryxia (ferric citrate) and Vafseo, both of which target complications of kidney disease, such as anemia and hyperphosphatemia.

READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts.

Disclosure: None. This article is originally published at Insider Monkey.